IP Library Granted Patent US 8,170,172
Granted Patent B2
US 8,170,172 · App. 12/518,645 · Granted May 1, 2012

Target bodies and uses thereof in the production of radioisotope materials

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,170,172
App. No.
12/518,645
Granted
May 1, 2012
Kind
B2
Abstract

A system and method are provided for reclaiming an enriched radioisotope starting material ( 14 ) from a target body ( 12 ). The system and method enable reclaiming the starting material in a relatively short time (e.g., several hours) after the target body's bombardment with energetic particles, greatly simplifying the target body's chemical processing, as well as reducing the cost of such processing (e.g., reducing the need for costly long-term storage). Specifically, a chemical protective layer ( 16 ) is disposed between a radioisotope starting material ( 14 ) and a base material ( 18 ) of the target body ( 12 ). After the target body is irradiated with a suitable source (e.g., particle accelerator), then the irradiated radioisotope starting material and be removed without removing the base material due to the protection provided by the chemical protective layer. The system and method also enable the operator to obtain three different radioisotopes in a single bombardment of the target body, further reducing cost of radioisotope production.

Claims (29)

1. A target body for use in the production of radioisotopes, the target body comprising:

a base comprising a thermally conductive material, and a coolant path;

a protective layer disposed on the base, the protective layer comprising chromium; and

a radioisotope starting material disposed on the base, the radioisotope starting material comprising thallium 203, wherein the protective layer is disposed between the base and the radioisotope starting material, wherein the protective layer is chemically resistant to removal by nitric acid, and the radioisotope starting material and the thermally conductive material of the base are susceptible to removal by nitric acid.

2. The target body of claim 1 , wherein the protective layer is electroplated on the base.

3. The target body of claim 2 , wherein the protective layer comprises a surface having a matte finish.

4. The target body of claim 1 , wherein the protective layer further comprises one or more of iridium, tantalum, tungsten, gold, niobium, aluminum, zirconium, or platinum, and combinations thereof.

5. The target body of claim 1 , wherein the base comprises one or more of copper, aluminum and combinations thereof.

6. A target body for use in the production of radioisotopes, the target body comprising:

a base comprising a coolant path, wherein the coolant path is a groove formed in the base;

a protective layer disposed on the base, the protective layer comprising an electroplated layer including chromium; and

a radioisotope starting material disposed on the base, wherein the protective layer is disposed between the base and the radioisotope starting material.

7. A target body for use in the production of radioisotopes, the target body comprising:

a base comprising a coolant path;

a protective layer disposed on the base, the protective layer comprising an electroplated layer including chromium; and

a radioisotope starting material disposed on the base, wherein the protective layer is disposed between the base and the radioisotope starting material,

wherein the base comprises aluminum and is coated with copper.

8. A target body for use in the production of radioisotopes, the target body comprising:

a base comprising a coolant path;

a protective layer disposed on the base, the protective layer comprising an electroplated layer including chromium; and

a radioisotope starting material disposed on the base, wherein the protective layer is disposed between the base and the radioisotope starting material,

wherein the radioisotope starting material comprises thallium 203.

9. A target body for use in the production of radioisotopes, the target body comprising:

a base comprising a thermally conductive material, and a coolant path, wherein the thermally conductive material is susceptible to chemical stripping using nitric acid;

a protective layer disposed directly on the base, wherein the protective layer is resistant to chemical stripping using nitric acid; and

a radioisotope starting material disposed directly on the protective layer such that the protective layer is disposed between the base and the radioisotope starting material, the radioisotope starting material being capable of forming radiopharmaceutical thallium 201 after being irradiated, and being susceptible to chemical stripping using nitric acid, wherein the protective layer is configured to inhibit the removal of the thermally conductive material during chemical stripping of the radioisotope material using nitric acid.

10. The target body of claim 9 , wherein the base comprises copper.

11. The target body of claim 10 , wherein the protective layer comprises chromium.

12. The target body of claim 11 , wherein the radioisotope starting material comprises thallium 203.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2009
From: UHLAND, WILLIAM CLAUDE
To: MALLINCKRODT INC.
Reel/Frame 022810/0093 →